In this article
Merck
on Thursday reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.
The pharmaceutical giant also narrowed its 2026 sales guidance and hiked its adjusted profit outlook, in part due to the underlying business and foreign exchange tailwinds.
Merck anticipates its 2026 revenue will come in between $65.8 billion and $67 billion, narrowing the low-end of that range from $65.5 billion. The company also expects adjusted earnings to be between $5.04 and $5.16 per share, up from a previous outlook of $5 to $5.15 per share.
